The shareholders of CS MEDICA A/S (”CS MEDICA” or the ”Company”) are hereby notified of the Annual General Meeting that will be held on Thursday, February 29, 2024, at 15:00 CET, at Fruebjergvej 3, 2100 Copenhagen, Denmark.  Shareholders will be entitled to vote by submitting postal vote forms before the meeting. Information about the resolutions passed at the meeting will be made public on February 29, 2024, after the general meeting has been held.

Agenda
1.   Election of chairman of the meeting.

2.   Presentation of the annual report with auditors’ report for adoption.

3.   Resolution concerning the appropriation of losses as recorded in the adopted annual report.

4.   Election of members to the board of directors.

5.   Election of the Company’s auditor.

6.   Any other business

The total number of votes as of the date of this notice is 12,322,635.

2. Presentation of the annual report with auditors’ report for adoption.
The annual report as approved by the board of directors will be presented to the general meeting for approval.

3. Resolution concerning the appropriation of losses as recorded in the adopted annual report.
The board of directors proposes that the result for the period 1 October 2022 – 30 September 2023 (DKK – 14.512.764) is carried forward to the following year.

4. Election of members to the board of directors.
The board members are proposed to be re-elected.

5. Election of auditor.
The board of directors proposes that the existing auditor (Christensen Kjærulff Statsautoriseret Revisionsaktieselskab) is re-elected.

Sign up for the Annual General Meeting
Send email to info@cs-medica.com

Power Of Attorney
Link >>

Registration
The registration date is 20 February 2024. Only those who are shareholders on this date have the right to participate and vote at the general meeting.

A shareholder has also the possibility of requesting an admission for a proxy holder who attends the general meeting on behalf of the shareholder. The request must be made, no later than 2 days before the general meeting, cf. section 5.9 of the articles of association. Such request must be made to e-mail info@cs-medica.com. The request must be received no later than 26 February 2024, at 11.59 PM (CET).  The shareholder must fill in and sign the proxy and postal voting form, which can be found on the Company’s website www.cs-medica.com. The proxy must bring the admission card and the original form to the general meeting.

Participation
To be entitled to participate in the general meeting, shareholders whose shares are registered in the name of a nominee must temporarily re-register their shares in their names in the share register. Such registration must be duly affected in the share register on 20 February 2024, and the shareholders must therefore advise their nominees well in advance of such date.

The shareholders have the right to ask questions about the issues on the agenda to be discussed at the general meeting. The questions can be made in writing before the general meeting or at the general meeting. The answer will – with the limitations that follow from the legislation – if possible be made at the general meeting or be made available to the shareholders no later than two weeks after the general meeting.

All material mentioned in this notice can be obtained from Gitte Lund Henriksen, e-mail glh@cs-medica.com. The material will only be forwarded by e-mail, and thus the e-mail address must be specified.

CS MEDICA A/S

On behalf of the board of directors
Jørgen Flemming Ladefoged, Chairman

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and operating within the pharmaceutical industry. The company combines science and nature with the purpose of creating over-the-counter treatments to fight autoimmune and stress-related diseases, built upon our knowledge of the endocannabinoid system, patients’ needs, and our experience in the pharmaceutical industry. We do so by pioneering scientific breakthroughs, expanding access to our treatments, understanding patients globally, and working to prevent the pain caused by the diseases we treat.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.

Tags: